Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret Showel

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Best Practice & Research. Clinical Haematology|November 23, 2015
Recent developments in HLA-haploidentical transplantationsMargaret Showel, Ephraim J Fuchs
Leukemia & Lymphoma|March 28, 2022
CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemiaBrandy Perkins, Margaret Showel, Laura Schoch, et al.
Leukemia & Lymphoma|July 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, et al.
Leukemia Research|September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studiesKelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Leukemia Research|September 5, 2017
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literatureKelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, et al.
Blood Advances|August 20, 2020
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J Symons, Marianna Zahurak, Yilin Cao, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Best Practice & Research. Clinical Haematology|November 23, 2015
Recent developments in HLA-haploidentical transplantationsMargaret Showel, Ephraim J Fuchs
Leukemia & Lymphoma|March 28, 2022
CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemiaBrandy Perkins, Margaret Showel, Laura Schoch, et al.
Leukemia & Lymphoma|July 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Jonathan A Webster, Meera Yogarajah, Marianna Zahurak, et al.
Leukemia Research|September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studiesKelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Leukemia Research|September 5, 2017
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literatureKelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, et al.
Blood Advances|August 20, 2020
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J Symons, Marianna Zahurak, Yilin Cao, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Pageof 1